31 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.
F. Hoffmann-La Roche
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
Chinese Academy of Sciences
Interaction Analysis of FABP4 Inhibitors by X-ray Crystallography and Fragment Molecular Orbital Analysis.
Ajinomoto
Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.
Chinese Academy of Sciences
Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands.
Okayama University 1-1-1
Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes.
Sichuan University
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.
University of Parma
New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein.
Chinese Academy of Sciences
Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.
Chinese Academy of Sciences
Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
University of Minnesota
N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors.
Biovitrum
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Bristol-Myers Squibb Pharmaceutical Research Institute
Optimization of potent, selective and orally bioavailable biphenyl scaffold as FABP4 inhibitors for anti-inflammation.
Fudan University
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
Guangdong Pharmaceutical University
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review.
Universita degli Studi di Catania
NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein.
Bristol-Myers Squibb Pharmaceutical Research Institute
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. An update from 2017 to early 2022.
University of Catania
Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors.
Biovitrum
Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.
Biovitrum
Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus.
Fudan University
Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation.
Chinese Academy of Sciences
Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor.
Fudan University
From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4.
Fudan University
Synthesis, ß-glucuronidase inhibition and molecular docking studies of hybrid bisindole-thiosemicarbazides analogs.
Universiti Teknologi Mara
Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
Bayer Intellectual Property
Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
Merck Sharp & Dohme